William L Carroll

List of Publications by Year
in descending order

355 papers	21,765 citations	10389 72 h-index	10445 139 g-index
357 all docs	357 docs citations	357 times ranked	16546 citing authors

#	Article	IF	Citations
1	Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2009, 360, 470-480.	27.0	1,260
2	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	27.0	1,161
3	Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 1663-1669.	1.6	944
4	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood, 2008, 111, 5477-5485.	1.4	751
5	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics, 2017, 49, 1211-1218.	21.4	693
6	Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2009, 27, 5175-5181.	1.6	643
7	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	16.8	621
8	Rearrangement of CRLF2 in B-progenitorâ€“ and Down syndromeâ€“associated acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1243-1246.	21.4	559
9	JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9414-9418.	7.1	516
10	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood, 2010, 115, 5312-5321.	1.4	503
11	Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1001-1005.	21.4	459
12	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood, 2007, 109, 926-935.	1.4	413
13	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	21.4	384
14	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group Study AALL0232. Journal of Clinical Oncology, 2016, 34, 2380-2388.	1.6	301
15	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Childrenâ€™s Oncology Group study AALL0232. Blood, 2015, 126, 964-971.	1.4	287
16	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6604.	12.8	281
17	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 290-294.	21.4	264
18	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	21.4	264

#	Article	IF	Citations
19	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	21.4	239
20	Targetable kinase gene fusions in high-risk B-ALL: a study from the Childrenâ€™s Oncology Group. Blood, 2017, 129, 3352-3361.	1.4	236
21	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2015, 313, 815.	7.4	234
22	Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study. Journal of Clinical Oncology, 2008, 26, 3756-3762.	1.6	211
23	Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 3971-3978.	1.6	210
24	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. Blood, 2012, 119, 3512-3522.	1.4	210
25	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute, 2013, 105, 733-742.	6.3	208
26	Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. Journal of Clinical Oncology, 2010, 28, 4755-4761.	1.6	203
27	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2009, 301, 393.	7.4	193
28	Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood, 2010, 115, 1394-1405.	1.4	192
29	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0622. Journal of Clinical Oncology, 2018, 36, 2306-2314.	1.6	185
30	Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood, 2011, 118, 5218-5226.	1.4	180
31	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 2008, 112, 4178-4183.	1.4	179
32	Mouse Ã— human heterohybridomas as fusion partners with human B cell tumors. Journal of Immunological Methods, 1986, 89, 61-72.	1.4	175
33	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood, 2018, 131, 995-999.	1.4	170
34	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 751-757.	1.6	165
35	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Childrenâ€™s Oncology Group AALL0434 Methotrexate Randomization. Journal of Clinical Oncology, 2018, 36, 2926-2934.	1.6	164
36	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood, 2018, 131, 1350-1359.	1.4	158

#	Article	IF	Citations
37	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood, 2013, 121, 485-488.	1.4	156
38	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood, 2006, 107, 4961-4967.	1.4	154
39	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2013, 60, 957-963.	1.5	149
40	Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 2006, 108, 711-717.	1.4	147
41	Childrenâ€™s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 3282-3293.	1.6	136
42	Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatric Blood and Cancer, 2006, 47, 130-140.	1.5	130
43	Five-Membered Ring Peroxide Selectively Initiates Ferroptosis in Cancer Cells. ACS Chemical Biology, 2016, 11, 1305-1312.	3.4	128
44	Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 2011, 118, 243-251.	1.4	126
45	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	21.4	126
46	Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2013, 31, 3397-3402.	1.6	125
47	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood, 2012, 119, 5201-5210.	1.4	123
48	Hybridoma fusion cell lines contain an aberrant kappa transcript. Molecular Immunology, 1988, 25, 991-995.	2.2	121
49	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
50	Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood, 2011, 118, 6043-6049.	1.4	118
51	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 1897-1905.	1.6	117
52	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia. JAMA Oncology, 2015, 1, 287.	7.1	114
53	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Childrenâ€™s Oncology Group (COG) Study AALL0434. Blood, 2014, 124, 1-1.	1.4	113
54	Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 2012, 119, 1872-1881.	1.4	110

#	Article	IF	Citations
55	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
56	The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Childrenâ€™s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood, 2014, 123, 2017-2025.	1.4	109
57	Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2020, 37, 867-882.e12.	16.8	108
58	A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia. Cancer, 2014, 120, 1417-1425.	4.1	107
59	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Childrenâ€™s Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2020, 38, 602-612.	1.6	107
60	Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 4376-4384.	1.6	102
61	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2015, 126, 1770-1776.	1.4	102
62	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature Medicine, 2013, 19, 1014-1022.	30.7	100
63	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Childrenâ€™s Oncology Group. Blood, 2018, 132, 815-824.	1.4	97
64	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. Journal of Clinical Oncology, 2014, 32, 3874-3882.	1.6	91
65	Reâ€induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatric Blood and Cancer, 2015, 62, 1171-1175.	1.5	89
66	MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood, 2015, 126, 2202-2212.	1.4	88
67	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2133-2140.	1.6	88
68	Biology and Treatment of Acute Lymphoblastic Leukemia. Pediatric Clinics of North America, 2008, 55, 1-20.	1.8	86
69	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood, 2014, 124, 1266-1276.	1.4	84
70	End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood, 2007, 109, 1810-1816.	1.4	83
71	Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 2753-2759.	1.6	82
72	Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. Blood, 2012, 119, 817-825.	1.4	80

#	Article	IF	Citations
73	Characterization of COVIDâ€19 disease in pediatric oncology patients: The New Yorkâ€New Jersey regional experience. Pediatric Blood and Cancer, 2021, 68, e28843.	1.5	78
74	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed Tâ€cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatric Blood and Cancer, 2015, 62, 1176-1183.	1.5	76
75	Anxiety, pain, and nausea during the treatment of standardâ€risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup. Cancer, 2016, 122, 1116-1125.	4.1	72
76	Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. Cancer, 2016, 122, 1608-1617.	4.1	69
77	Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood, 2011, 117, 3010-3015.	1.4	67
78	Identification of gene expression profiles that segregate patients with childhood leukemia. Clinical Cancer Research, 2002, 8, 3118-30.	7.0	67
79	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study <scp>AALL0331</scp>. International Journal of Cancer, 2016, 138, 332-339.	5.1	66
80	Bortezomib reinduction chemotherapy in highâ€risk <scp>ALL</scp> in first relapse: a report from the Children's Oncology Group. British Journal of Haematology, 2019, 186, 274-285.	2.5	65
81	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€•or â€œBCR-ABL1-Likeâ€) Signature For Therapeutic Targeting and Clinical Intervention. Blood, 2013, 122, 826-826.	1.4	65
82	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood, 2015, 126, 69-75.	1.4	64
83	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2017, 35, 2527-2534.	1.6	64
84	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood, 2013, 121, 148-155.	1.4	61
85	Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. British Journal of Haematology, 2014, 167, 87-99.	2.5	61
86	Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3). Pediatric Blood and Cancer, 2015, 62, 419-426.	1.5	61
87	Experimental validation of simulation methods for bi-directional transmission properties at the daylighting performance level. Energy and Buildings, 2006, 38, 878-889.	6.7	56
88	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. Journal of Clinical Oncology, 2021, 39, 1437-1447.	1.6	56
89	Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906. Pediatric Blood and Cancer, 2011, 57, 569-577.	1.5	55
90	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. Journal of Clinical Oncology, 2018, 36, 10500-10500.	1.6	54

#	Article	IF	Citations
91	Loss of TBL1XR1 Disrupts Glucocorticoid Receptor Recruitment to Chromatin and Results in Glucocorticoid Resistance in a B-Lymphoblastic Leukemia Model. Journal of Biological Chemistry, 2014, 289, 20502-20515.	3.4	52
92	Childhood bone marrow monosomy 7 syndrome: A familial disorder?. Journal of Pediatrics, 1985, 107, 578-580.	1.8	51
93	Expression of the c-Myc Protein in Childhood Medulloblastoma. Journal of Pediatric Hematology/Oncology, 1998, 20, 18-25.	0.6	51
94	Genetic Studies of a Cluster of Acute Lymphoblastic Leukemia Cases in Churchill County, Nevada. Environmental Health Perspectives, 2007, 115, 158-164.	6.0	51
95	Epigenetic deregulation in pediatric acute lymphoblastic leukemia. Epigenetics, 2014, 9, 459-467.	2.7	51
96	Progress and Prospects in Pediatric Leukemia. Current Problems in Pediatric and Adolescent Health Care, 2016, 46, 229-241.	1.7	50
97	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2019, 37, 780-789.	1.6	48
98	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very highâ€risk stratum of patients with newly diagnosed highâ€risk Bâ€lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer, 2018, 124, 1150-1159.	4.1	46
99	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Childrenâ€™s Oncology Group trial AALL0631. Leukemia, 2021, 35, 1279-1290.	7.2	46
100	The Nucleophosmin-Anaplastic Lymphoma Kinase Fusion Protein Induces c-Myc Expression in Pediatric Anaplastic Large Cell Lymphomas. American Journal of Pathology, 2002, 161, 875-883.	3.8	43
101	Clinical and Laboratory Biology of Childhood Acute Lymphoblastic Leukemia. Journal of Pediatrics, 2012, 160, 10-18.	1.8	41
102	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Childrenâ€™s Oncology Group Study AALL1131. Journal of Clinical Oncology, 2020, 38, 2628-2638.	1.6	41
103	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Childrenâ€™s Oncology Group (COG). Leukemia, 2018, 32, 1370-1379.	7.2	40
104	Childhood Leukemia â€" New Advances and Challenges. New England Journal of Medicine, 2004, 351, 601-603.	27.0	39
105	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2017, 35, 2700-2707.	1.6	38
106	Imatinib resistant BCRâ€ABL1 mutations at relapse in children with <scp>P</scp>h⁺<scp>ALL</scp>: a <scp>C</scp>hildren's <scp>O</scp>ncology <scp>G</scp>roup (<scp>COG</scp>) study. British Journal of Haematology, 2012, 157, 507-510.	2.5	36
107	MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica, 2018, 103, 830-839.	3.5	35
108	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). Blood, 2013, 122, 3903-3903.	1.4	35

#	Article	IF	Citations
109	The Molecular Biology of Pediatric Lymphomas. Journal of Pediatric Hematology/Oncology, 1998, 20, 282-296.	0.6	34
110	The Biology of Relapsed Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2014, 36, 413-418.	0.6	34
111	New targeted therapies for relapsed pediatric acute lymphoblastic leukemia. Expert Review of Anticancer Therapy, 2017, 17, 725-736.	2.4	34
112	A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia. Oncotarget, 2015, 6, 16527-16542.	1.8	34
113	Childhood acute lymphoblastic leukemia in the age of genomics. Pediatric Blood and Cancer, 2006, 46, 570-578.	1.5	32
114	A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination With Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL). Journal of Pediatric Hematology/Oncology, 2014, 36, 458-463.	0.6	32
115	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Childrenâ€™s Oncology Group study. Blood, 2017, 129, 1919-1926.	1.4	32
116	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. Cancer Genetics, 2019, 238, 62-68.	0.4	32
117	Immune-Based Therapies in Acute Leukemia. Trends in Cancer, 2019, 5, 604-618.	7.4	32
118	c-mycHypermutation in Burkitt's Lymphoma. Leukemia and Lymphoma, 1992, 8, 431-439.	1.3	31
119	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. Pediatric Blood and Cancer, 2015, 62, 414-418.	1.5	31
120	Longitudinal analysis of qualityâ€ofâ€life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer, 2018, 124, 571-579.	4.1	31
121	Integrin Î±6 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood, 2020, 136, 210-223.	1.4	31
122	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2019, 37, 10008-10008.	1.6	31
123	Development of the Human Antibody Repertoire. Pediatric Research, 1992, 32, 257-263.	2.3	30
124	Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene, 1997, 15, 1937-1946.	5.9	29
125	Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. Pediatric Blood and Cancer, 2012, 59, 834-839.	1.5	29
126	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. Haematologica, 2020, 106, 46-55.	3.5	29

#	Article	IF	Citations
127	Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Review of Hematology, 2009, 2, 145-158.	2.2	28
128	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. Blood, 2014, 124, 791-791.	1.4	28
129	HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 2565-2567.	1.3	27
130	Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. Leukemia, 2018, 32, 1393-1403.	7.2	27
131	Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leukemia and Lymphoma, 2016, 57, 1938-1941.	1.3	26
132	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group Study AALL03N1. Journal of Clinical Oncology, 2017, 35, 1730-1736.	1.6	26
133	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Childrenâ€™s Oncology Group AALL07P4. Leukemia and Lymphoma, 2019, 60, 1740-1748.	1.3	25
134	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica, 2019, 104, 986-992.	3.5	25
135	ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2020, 26, 256-264.	7.0	25
136	Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Childrenâ€™s Oncology Group (COG) Study AALL0031.. Blood, 2007, 110, 4-4.	1.4	25
137	A Novel Intron Element Operates Posttranscriptionally To Regulate Human N-myc Expression. Molecular and Cellular Biology, 1999, 19, 155-163.	2.3	24
138	Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?. Pediatric Blood and Cancer, 2005, 45, 876-880.	1.5	24
139	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of inductionâ€”A Children's Oncology Group (COG) Study.. Blood, 2009, 114, 9-9.	1.4	24
140	Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance. Pediatric Blood and Cancer, 2014, 61, 1779-1785.	1.5	23
141	Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): Review from an international consensus conference. Pediatric Blood and Cancer, 2010, 54, 872-878.	1.5	22
142	Immunotherapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: Advances and Ongoing Challenges. Paediatric Drugs, 2020, 22, 485-499.	3.1	21
143	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. Blood, 2011, 118, 573-573.	1.4	21
144	GENE EXPRESSION PROFILING. Hematology/Oncology Clinics of North America, 2001, 15, 911-930.	2.2	20

#	Article	IF	Citations
145	The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Contextâ€“Dependent Manner in Pediatric Acute Lymphoblastic Leukemia. Molecular Cancer Research, 2020, 18, 1153-1165.	3.4	20
146	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions. Cancers, 2021, 13, 1847.	3.7	20
147	Diversity of Immunoglobulin Light Chain Usage in the Human Immune Response to Haemophilus influenzae Type b Capsular Polysaccharide. Pediatric Research, 1993, 33, 307-311.	2.3	19
148	Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2021, 39, 1540-1552.	1.6	19
149	Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Childrenâ€™s Oncology Group (COG).. Blood, 2008, 112, 898-898.	1.4	19
150	Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Childrenâ€™s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.. Blood, 2006, 108, 1865-1865.	1.4	18
151	Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2. Cancer, 2004, 101, 2106-2115.	4.1	17
152	Outcome of Children with Standardâ€Risk Tâ€Lineage Acute Lymphoblastic Leukemiaâ€”Comparison among Different Treatment Strategies. Pediatric Blood and Cancer, 2016, 63, 255-261.	1.5	17
153	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Childrenâ€™s Oncology Group. Blood Advances, 2019, 3, 1647-1656.	5.2	17
154	Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2019, 18, 1887-1895.	4.1	17
155	Integrative Analysis of Ikaros-Dependent Changes of Transcriptional Regulation and Tyrosine Phosphorylation Events in Ph+ ALL. Blood, 2012, 120, 528-528.	1.4	17
156	Therapies on the horizon for childhood acute lymphoblastic leukemia. Current Opinion in Pediatrics, 2016, 28, 12-18.	2.0	16
157	Race and Outcome in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2003, 290, 2061.	7.4	15
158	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. Blood, 2009, 114, 704-704.	1.4	15
159	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Childrenâ€™s Oncology Group (COG) Study AALL0331. Blood, 2014, 124, 793-793.	1.4	15
160	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	1.4	14
161	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Childrenâ€™s Oncology Group Study AALL0232. Leukemia, 2022, 36, 648-655.	7.2	14
162	Rational drug combinations with CDK4/6 inhibitors in acute lymphoblastic leukemia. Haematologica, 2022, 107, 1746-1757.	3.5	14

#	Article	IF	Citations
163	Pancytopenia with Myelofibrosis. Clinical Pediatrics, 1986, 25, 106-108.	0.8	13
164	Cost comparison by treatment arm and centerâ€level variations in cost and inpatient days on the phase <scp>III</scp> highâ€risk B acute lymphoblastic leukemia trial <scp>AALL</scp>0232. Cancer Medicine, 2018, 7, 3-12.	2.8	13
165	NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. Leukemia, 2018, 32, 2527-2535.	7.2	13
166	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Childrenâ€™s Oncology Group (COG) AALL0331. Blood, 2013, 122, 837-837.	1.4	13
167	Clinical Outcome of 640 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005. Blood, 2008, 112, 568-568.	1.4	13
168	Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Childrenâ€™s Oncology Group Study 1991. Blood, 2008, 112, 9-9.	1.4	12
169	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. Blood, 2011, 118, 1510-1510.	1.4	12
170	Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. Blood, 2015, 126, 794-794.	1.4	12
171	Sexâ€based disparities in outcome in pediatric acute lymphoblastic leukemia: a Childrenâ€™s Oncology Group report. Cancer, 2022, 128, 1863-1870.	4.1	12
172	Safety in numbers: hyperdiploidy and prognosis. Blood, 2013, 121, 2374-2376.	1.4	11
173	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Childrenâ€™s Oncology Group. Haematologica, 2019, 104, e517-e520.	3.5	11
174	Double Delayed Intensification (DDI) Is Equivalent to Single DI (SDI) in Children with National Cancer Institute (NCI) Standard-Risk Acute Lymphoblastic Leukemia (SR-ALL) Treated on Childrenâ€™s Cancer Group (CCG) Clinical Trial 1991 (CCG-1991).. Blood, 2006, 108, 146-146.	1.4	11
175	Outcomes for B-Precursor Patients in Legacy Childrenâ€™s Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Childrenâ€™s Oncology Group (COG) Report.. Blood, 2007, 110, 847-847.	1.4	11
176	Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Childrenâ€™s Oncology Group AALL0631 trial. Haematologica, 2022, 107, 1205-1208.	3.5	11
177	Immunoglobulin Variable Region Usage in Human Intestinal B Lymphocytes. Clinical Immunology and Immunopathology, 1994, 71, 240-245.	2.0	10
178	Late isolated central nervous system relapse in childhood Bâ€cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. Pediatric Blood and Cancer, 2021, 68, e29256.	1.5	10
179	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. Blood, 2009, 114, 85-85.	1.4	10
180	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. Blood, 2012, 120, 2529-2529.	1.4	10

#	Article	IF	Citations
181	Analysis of hypermutation in immunoglobulin heavy chain passenger transgenes. European Journal of Immunology, 1996, 26, 1058-1062.	2.9	9
182	Somatic Hypermutation in T-Independent and T-Dependent Immune Responses toHaemophilus influenzaeType b Polysaccharide. Clinical Immunology and Immunopathology, 1998, 89, 240-246.	2.0	9
183	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Childrenâ€™s Oncology Group Study AALL08P1. Journal of Pediatric Hematology/Oncology, 2016, 38, 409-417.	0.6	9
184	Evolution of the Epigenetic Landscape in Childhood B Acute Lymphoblastic Leukemia and Its Role in Drug Resistance. Cancer Research, 2020, 80, 5189-5202.	0.9	9
185	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Childrenâ€™s Oncology Group AALL0622.. Journal of Clinical Oncology, 2015, 33, 10006-10006.	1.6	9
186	Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1977-1986.	4.9	8
187	Screening for gene mutations: will identification ofNT5C2mutations help predict the chance of relapse in acute lymphoblastic leukemia?. Expert Review of Hematology, 2013, 6, 223-224.	2.2	8
188	Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient. Journal of Pediatric Hematology/Oncology, 2016, 38, e21-e25.	0.6	8
189	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. Pediatric Blood and Cancer, 2019, 66, e27681.	1.5	8
190	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Childrenâ€™s Oncology Group Studies P9904 and P9905. Leukemia, 2020, 34, 1006-1016.	7.2	8
191	Inhibition Of The Wnt Pathway Leads To Improved Chemosensitivity In Pediatric Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1428-1428.	1.4	8
192	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. Blood, 2013, 122, 232-232.	1.4	8
193	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. Blood, 2013, 122, 825-825.	1.4	8
194	Beating the Clock in T-cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2017, 23, 873-875.	7.0	7
195	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	4.7	7
196	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. Blood, 2018, 132, 35-35.	1.4	7
197	Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia. Blood, 2008, 112, 2925-2925.	1.4	7
198	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. Blood, 2009, 114, 1580-1580.	1.4	7

#	Article	IF	Citations
199	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. Blood, 2010, 116, 2752-2752.	1.4	7
200	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. Blood, 2012, 120, 137-137.	1.4	7
201	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Childrenâ€™s Oncology Group (COG) report.. Journal of Clinical Oncology, 2020, 38, 10510-10510.	1.6	7
202	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 618-618.	1.4	6
203	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR) Tj ETQq1 1 0.784314 rgBT /Over 1303-1303.	1.4	6
204	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Childrenâ€™s Oncology Group study AALL0232.. Journal of Clinical Oncology, 2012, 30, CRA9508-CRA9508.	1.6	6
205	Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Childrenâ€™s Oncology Group AALL1131.. Journal of Clinical Oncology, 2015, 33, 10007-10007.	1.6	6
206	Definition of the Human N-myc Promoter Region during Development in a Transgenic Mouse Model. Pediatric Research, 1999, 46, 255-262.	2.3	6
207	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. Blood, 2009, 114, 2598-2598.	1.4	6
208	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	1.4	6
209	The Absence of Ongoing Immunoglobulin Gene Hypermutation Suggests a Distinct Mechanism for c-myc Mutation in Endemic BurkittÊ¼s Lymphoma. Journal of Pediatric Hematology/Oncology, 1996, 18, 29-35.	0.6	5
210	Potential of Gene Expression Profiling in the Management of Childhood Acute Lymphoblastic Leukemia. Paediatric Drugs, 2007, 9, 149-156.	3.1	5
211	Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia â€. Pediatric Blood and Cancer, 2020, 67, e28306.	1.5	5
212	Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children's Oncology Group Pilot Study. Blood, 2020, 136, 20-21.	1.4	5
213	Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Childrenâ€™s Oncology Group (COG) Study.. Blood, 2006, 108, 219-219.	1.4	5
214	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. Blood, 2009, 114, 907-907.	1.4	5
215	High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Childrenâ€™s Oncology Group (COG) Study (AALL03N1). Blood, 2013, 122, 59-59.	1.4	5
216	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Childrenâ€™s Oncology Group (COG) Study AALL0434. Blood, 2014, 124, 3649-3649.	1.4	5

#	Article	IF	Citations
217	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). Blood, 2015, 126, 807-807.	1.4	5
218	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. Blood, 2016, 128, 3965-3965.	1.4	5
219	ITIM-Containing Inhibitory Receptors Are Required to Balance Oncogenic Signaling Strength in Ph+ ALL. Blood, 2012, 120, 291-291.	1.4	5
220	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	1.4	5
221	Individualized therapy for childhood acute lymphoblastic leukemia. Personalized Medicine, 2005, 2, 349-361.	1.5	4
222	Building better therapy for children with acute lymphoblastic leukemia. Cancer Cell, 2005, 7, 289-291.	16.8	4
223	State of the Art Discovery with Tumor Profiling in Pediatric Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e601-e607.	3.8	4
224	Klinefelter syndrome and 47,<scp>XYY</scp> syndrome in children with B cell acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 843-846.	2.5	4
225	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. Blood, 2019, 134, 1293-1293.	1.4	4
226	Factors Influencing Survival after Relapse from Childhood ALL: A Childrenâ€™s Oncology Group Study.. Blood, 2006, 108, 1855-1855.	1.4	4
227	Changes in the Delivery of Standard Chemotherapeutic Agents during Induction Affect Early Measures of Minimal Residual Disease (MRD): POG 9900 for Patients with B-Precursor Low and Standard Risk ALL.. Blood, 2006, 108, 2272-2272.	1.4	4
228	AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.. Blood, 2009, 114, 3076-3076.	1.4	4
229	Report On Excessive Induction Toxicity in Infants with ALL Enrolled On COG Protocol AALL0631: A Children's Oncology Group Study.. Blood, 2009, 114, 3091-3091.	1.4	4
230	The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse. Blood, 2012, 120, 470-470.	1.4	4
231	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. Blood, 2013, 122, 824-824.	1.4	4
232	Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433. Blood, 2014, 124, 684-684.	1.4	4
233	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. Blood, 2015, 126, 691-691.	1.4	4
234	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. Blood, 2016, 128, 451-451.	1.4	4

#	Article	IF	Citations
235	Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2013, 31, 10001-10001.	1.6	4
236	Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Childrenâ€™s Oncology Group (COG) trials.. Journal of Clinical Oncology, 2015, 33, 10035-10035.	1.6	4
237	Impact of asparaginase discontinuation on outcome in childhood ALL: A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2019, 37, 10005-10005.	1.6	4
238	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. Blood, 2012, 120, 289-289.	1.4	4
239	Refining prognosis in BCR-ABL1â€“positive ALL. Blood, 2014, 123, 1626-1627.	1.4	3
240	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. Blood, 2021, 137, 1550-1552.	1.4	3
241	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Childrenâ€™s Oncology Group AALL1131.. Journal of Clinical Oncology, 2021, 39, 10004-10004.	1.6	3
242	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Advances, 2021, 5, 2890-2900.	5.2	3
243	Minimal Residual Disease(MRD) in Childhood Acute Lymphoblastic Leukemia(ALL) in Relapse. A Childrenâ€™s Oncology Group (COG) Study.. Blood, 2004, 104, 324-324.	1.4	3
244	Nelarabine Can Be Safely Incorporated into an Intensive, Multiagent Chemotherapy Regimen for the Treatment of T-Cell Acute Lymphocytic Leukemia (ALL) in Children: A Report of the Childrenâ€™s Oncology Group (COG) AALL00P2 Protocol for T-Cell Leukemia.. Blood, 2006, 108, 1864-1864.	1.4	3
245	Outcomes of Children with First Marrow Relapse: Results from Childrenâ€™s Oncology Group (COG) Study AALL01P2.. Blood, 2006, 108, 1871-1871.	1.4	3
246	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. Blood, 2011, 118, 1440-1440.	1.4	3
247	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. Blood, 2011, 118, 743-743.	1.4	3
248	Effects of Dexamethasone (DEX) Vs Prednisone (PDN) and High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Asparaginase (C-MTX/ASNase) On Osteonecrosis (ON) Incidence in Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group (COG) Study AALL0232. Blood, 2012, 120, 665-665.	1.4	3
249	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. Blood, 2015, 126, 82-82.	1.4	3
250	The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Childrenâ€™s Oncology Group (COG) protocol AALL0433.. Journal of Clinical Oncology, 2014, 32, 10014-10014.	1.6	3
251	Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG E. coli L-asparaginase): Results from Childrenâ€™s Oncology Group (COG) study AALL07P4.. Journal of Clinical Oncology, 2016, 34, 10508-10508.	1.6	3
252	Administration of Erwinia Asparaginase (ErwinaseÂ®) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG). Blood, 2010, 116, 2134-2134.	1.4	3

#	Article	IF	Citations
253	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 530-530.	1.4	3
254	Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Childrenâ€™s Oncology Group (COG) AALL0932.. Journal of Clinical Oncology, 2020, 38, 10509-10509.	1.6	3
255	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. Blood, 2021, 138, 211-211.	1.4	3
256	A shuttle vector system for the investigation of immunoglobulin gene hypermutation: Absence of enhanced mutability in intermediate B cell lines. Molecular Immunology, 1992, 29, 1005-1011.	2.2	2
257	Reply to I.J. Cohen. Journal of Clinical Oncology, 2017, 35, 3989-3991.	1.6	2
258	From Favorable Histology to Relapse: The Clonal Evolution of a Wilms Tumor. Pediatric and Developmental Pathology, 2020, 23, 167-171.	1.0	2
259	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). Blood, 2018, 132, 1000-1000.	1.4	2
260	Effective Targeting of Leukemic Cells in Children with B-Precursor Acute Lymphoblastic Leukemia Treated with Anti-CD22 (Epratuzumab). A Childrenâ€™s Oncology Group (COG) Study.. Blood, 2006, 108, 2585-2585.	1.4	2
261	Genome-Wide Profiling of High-Risk Pediatric Acute Lymphoblastic Leukemia (ALL): The ALL Pilot Project for the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) Initiative.. Blood, 2007, 110, 229-229.	1.4	2
262	Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group Study (COG).. Blood, 2007, 110, 583-583.	1.4	2
263	Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse â€“ a Children's Oncology Group (COG) Study (AALL03N1). Blood, 2012, 120, 882-882.	1.4	2
264	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2015, 126, 694-694.	1.4	2
265	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. Blood, 2016, 128, 1086-1086.	1.4	2
266	Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.. Journal of Clinical Oncology, 2012, 30, 9548-9548.	1.6	2
267	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Childrenâ€™s Oncology Group (COG) study AALL03N1.. Journal of Clinical Oncology, 2014, 32, 10013-10013.	1.6	2
268	Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in a Second Remission after an Isolated Central Nervous System Relapse.. Blood, 2006, 108, 49-49.	1.4	2
269	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. Blood, 2009, 114, 2606-2606.	1.4	2
270	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. Blood, 2011, 118, 739-739.	1.4	2

#	Article	IF	Citations
271	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. Blood, 2012, 120, 877-877.	1.4	2
272	Selective Right Mainstem Bronchus Intubation as a Treatment for Persistent Left Pneumothorax in the Newborn. Clinical Pediatrics, 1983, 22, 450-452.	0.8	1
273	On target for advances in the treatment of childhood acute lymphoblastic leukemia. Blood, 2005, 105, 438-439.	1.4	1
274	The Immunoglobulin Gene Repertoire to Haemophilus influenzae Type b. Annals of the New York Academy of Sciences, 1995, 764, 374-377.	3.8	1
275	The potential of precision medicine for childhood acute lymphoblastic leukemia: opportunities and challenges. Expert Review of Precision Medicine and Drug Development, 2018, 3, 343-356.	0.7	1
276	Targeting a major hub of cell fate decisions â€“ the mitochondrial-associated membrane. Haematologica, 2019, 104, 419-421.	3.5	1
277	dMMR and thiopurines strand TP53 for ALL relapse. Nature Cancer, 2021, 2, 777-779.	13.2	1
278	A Gene Expression Classifier for Improved Risk Classification and Outcome Prediction in Pediatric Acute Lymphoblastic Leukemia (ALL).. Blood, 2005, 106, 762-762.	1.4	1
279	Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Childrenâ€™s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL.. Blood, 2006, 108, 283-283.	1.4	1
280	Children with t(12;21)/TEL-AML1-Positive Acute Lymphoblastic Leukemia Exhibit a Distinct Germline Genomic Signature.. Blood, 2007, 110, 760-760.	1.4	1
281	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Childrenâ€™s Oncology Group (COG) Study AALL0031.. Blood, 2008, 112, 911-911.	1.4	1
282	Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.. Blood, 2009, 114, 2389-2389.	1.4	1
283	Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.. Blood, 2009, 114, 320-320.	1.4	1
284	Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial. Blood, 2010, 116, 2757-2757.	1.4	1
285	Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991. Blood, 2010, 116, 497-497.	1.4	1
286	A Randomized Trial of Sirolimus-Based Graft Versus Host Disease (GVHD) Prophylaxis After Hematopoietic Stem Cell Transplantation (HSCT) in Selected Patients with CR1 and CR2 ALL: Results From Children's Oncology Group Study ASCT0431. Blood, 2011, 118, 837-837.	1.4	1
287	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 60-60.	1.4	1
288	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. Blood, 2014, 124, 367-367.	1.4	1

#	Article	IF	Citations
289	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). Blood, 2016, 128, 758-758.	1.4	1
290	Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the Childrenâ€™s Oncology Group (COG) study AALL0331.. Journal of Clinical Oncology, 2013, 31, 10002-10002.	1.6	1
291	The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Childrenâ€™s Oncology Group (COG) Studies AALL0331 and AALL0232.. Journal of Clinical Oncology, 2014, 32, 10016-10016.	1.6	1
292	Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Childrenâ€™s Oncology Group Study 1991. Blood, 2008, 112, 701-701.	1.4	1
293	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. Blood, 2008, 112, 14-14.	1.4	1
294	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2010, 116, 8-8.	1.4	1
295	Vorinostat Reverses Relapse-Specific Drug Resistance Gene Expression Signatures In Childhood Acute Lymphoblastic Leukemia (ALL).. Blood, 2010, 116, 3630-3630.	1.4	1
296	Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG e. coli L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.. Journal of Clinical Oncology, 2012, 30, 9543-9543.	1.6	1
297	Deletions In TBL1XR1 Results In Glucocorticoid Resistance By Decreasing Glucocorticoid Signaling In Childhood B-Lymphoblastic Leukemia. Blood, 2013, 122, 602-602.	1.4	1
298	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	1.4	1
299	NT5C2 As a Major Contributor to Thiopurine Resistance at ALL Relapse Via Multiple Mechanisms. Blood, 2015, 126, 446-446.	1.4	1
300	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. Blood, 2016, 128, 455-455.	1.4	1
301	Eliminating a gold standard in childhood acute lymphoblastic leukemia?. Pediatric Blood and Cancer, 2006, 47, 242-244.	1.5	0
302	â€œWhen can I go home?â€â€”seeking ways to lower the burden on patients and families. Pediatric Blood and Cancer, 2008, 51, 318-319.	1.5	0
303	The ASPHO 2018 Distinguished Career Award goes to Dr. Michael P. Link. Pediatric Blood and Cancer, 2018, 65, e26987.	1.5	0
304	Reply to A. K. Agrawal et al. Journal of Clinical Oncology, 2021, 39, 695-696.	1.6	0
305	Prognostic Impact of CNS-2 status in T-ALL: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2021, 39, 10003-10003.	1.6	0
306	Gene Expression Pathways That Distinguish Diagnosis and Relapse in Childhood Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 848-848.	1.4	0

#	Article	IF	Citations
307	Gene Signatures Predictive of Outcome in Higher Risk Childhood Acute Lymphoblastic Leukemia (ALL).. Blood, 2005, 106, 1449-1449.	1.4	0
308	Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Childrenâ€™s Oncology Group Study.. Blood, 2007, 110, 1422-1422.	1.4	0
309	Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Childrenâ€™s Oncology Group.. Blood, 2007, 110, 758-758.	1.4	0
310	Genome-Wide Profiling Reveals Recurring Molecular Defects in Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Childrenâ€™s Oncology Group Study.. Blood, 2007, 110, 725-725.	1.4	0
311	Expression Profiling Identifies Novel Genetic Subgroups with Distinct Clinical Features and Outcome in High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia (B-ALL). A Childrenâ€™s Oncology Group Study.. Blood, 2007, 110, 1430-1430.	1.4	0
312	Evolution of Gene Expression Signatures in Relapsed Childhood Acute Lymphoblastic Leukemia Differs Based on Timing of Relapse.. Blood, 2008, 112, 3345-3345.	1.4	0
313	Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non-Down Syndrome Patients.. Blood, 2008, 112, 1203-1203.	1.4	0
314	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Childrenâ€™s Oncology Group (COG) Study.. Blood, 2008, 112, 2256-2256.	1.4	0
315	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Childrenâ€™s Oncology Group Trials.. Blood, 2008, 112, 1514-1514.	1.4	0
316	Deletion of IKZF1 (Ikaros) Predicts Poor Outcome and Impaired Maturation in B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2008, 112, 427-427.	1.4	0
317	Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Childrenâ€™s Oncology Group (COG).. Blood, 2008, 112, 917-917.	1.4	0
318	Up-Regulation of Genes Involved in Folate Metabolism Characterize Late but Not Early Relapse in Childhood Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 1733-1733.	1.4	0
319	Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.. Blood, 2009, 114, 2634-2634.	1.4	0
320	Early Response Characteristics and Blast Cytogenetic FEatures In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. Blood, 2010, 116, 414-414.	1.4	0
321	Phase 2 Results of Clofarabine In Combination with Etoposide and Cyclophosphamide In Pediatric Patients with Refractory or Relapsed Acute Lymphoblastic Leukemia. Blood, 2010, 116, 866-866.	1.4	0
322	Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (< 90 Days vs. > 90 Days): A Children's Oncology Group Study. Blood, 2010, 116, 412-412.	1.4	0
323	High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL) Identifies Relapse Specific Mutations and Expression. Blood, 2010, 116, 3233-3233.	1.4	0
324	Epigenetic Modulation Leads to Re-Expression of Relapse Specific Silenced Genes and Induces Chemosensitivity in Childhood Acute Lymphoblastic Leukemia (ALL),. Blood, 2011, 118, 3455-3455.	1.4	0

#	Article	IF	Citations
325	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL):Â A report from the Childrenâ€™s Oncology Group study AALL0232.. Journal of Clinical Oncology, 2012, 30, CRA9508-CRA9508.	1.6	0
326	Relapse-specific mutations in cytosolic 5â€™-nucleotidase II in childhood acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2012, 30, 9507-9507.	1.6	0
327	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. Blood, 2012, 120, 1300-1300.	1.4	0
328	Suppressor of Cytokine Signaling (SOCS) Molecules Are Critical to Balance Oncogenic Signaling Strength in Ph+ ALL.. Blood, 2012, 120, 2563-2563.	1.4	0
329	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. Blood, 2012, 120, 776-776.	1.4	0
330	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. Blood, 2012, 120, 2505-2505.	1.4	0
331	Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.. Blood, 2012, 120, 2565-2565.	1.4	0
332	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3868-3868.	1.4	0
333	Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway In Glucocorticoid Resistance In Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1296-1296.	1.4	0
334	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. Blood, 2013, 122, 229-229.	1.4	0
335	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood, 2014, 124, 612-612.	1.4	0
336	MAPK Signaling Cascades Mediate Distinct Glucocorticoid Resistance Mechanisms in Pediatric B-Precursor ALL. Blood, 2014, 124, 789-789.	1.4	0
337	Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. Blood, 2014, 124, 792-792.	1.4	0
338	ÂResource Utilization and Cost Analysis By Treatment Arm on the Childrenâ€™s Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Childrenâ€™s Oncology Group. Blood, 2014, 124, 210-210.	1.4	0
339	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Childrenâ€™s Oncology Group (COG) Study (AALL03N1). Blood, 2014, 124, 369-369.	1.4	0
340	Neurocognitive function of children treated for high-risk B-acute lymphoblastic leukemia (HR-ALL) randomized to Capizzi (CMTX) versus high-dose methotrexate (HDMTX): A report from the Childrenâ€™s Oncology Group (COG).. Journal of Clinical Oncology, 2015, 33, 10002-10002.	1.6	0
341	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. Blood, 2016, 128, 4083-4083.	1.4	0
342	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. Blood, 2016, 128, 2906-2906.	1.4	0

#	Article	IF	Citations
343	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. Blood, 2016, 128, 759-759.	1.4	0
344	Using Whole Exome Sequencing in Pediatric Acute Lymphoblastic Leukemia Germline, Diagnosis, and Relapse Trios to Discover Novel Relapse Enriched Mutations for Clonal Backtracking By Ddpcr. Blood, 2016, 128, 4085-4085.	1.4	0
345	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-RearrangedAcute Lymphoblastic Leukemia. Blood, 2016, 128, 907-907.	1.4	0
346	Measurement of Phosphorylated ERK As a Prognostic and Predictive Marker for MEK Inhibition in Pediatric B-Lymphoblastic Leukemia: A Pilot Study. Blood, 2016, 128, 1739-1739.	1.4	0
347	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. Journal of Clinical Oncology, 2017, 35, 10514-10514.	1.6	0
348	The NSD2 p.E1099K Mutation in Relapse Pediatric Acute Lymphoblastic Leukemia Is Linked to Mercaptopurine Resistance. Blood, 2018, 132, 3962-3962.	1.4	0
349	NSD2 Mutations in Pediatric ALL Leads to a Distinct Gene Expression Profile and Epigenetic Landscape That Is Cell Context Specific. Blood, 2018, 132, 3905-3905.	1.4	0
350	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. Blood, 2018, 132, 659-659.	1.4	0
351	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. Blood, 2021, 138, 2382-2382.	1.4	0
352	Non-Classical Monocyte Abundance Is an Independent Adverse Risk Factor for Relapse in Pediatric B-ALL. Blood, 2021, 138, 1316-1316.	1.4	0
353	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. Blood, 2020, 136, 38-39.	1.4	0
354	The new reality is virtual. Pediatric Blood and Cancer, 2022, 69, e29774.	1.5	0
355	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2022, 40, 7000-7000.	1.6	0